CAMBRIDGE, Mass. — MindImmune has secured a $5 million strategic investment from the Alzheimer’s Drug Discovery Foundation to support development of its lead therapeutic candidate aimed at treating Alzheimer’s disease through immune-based mechanisms.
The funding will help accelerate research on MITI-101, a first-in-class therapeutic program designed to target immune pathways believed to drive neuroinflammation and neurodegeneration in Alzheimer’s disease.
“This significant funding underscores growing scientific momentum around immune-mediated mechanisms in Alzheimer’s and positions MindImmune at the forefront of a new wave of therapeutic innovation,” the company said in a statement.
“Alzheimer’s disease remains one of the most urgent and complex challenges in medicine,” said Stevin Zorn, Chief Science Officer of MindImmune. “This support from the ADDF empowers us to push the boundaries of immune biology in neurodegeneration and rapidly advance MITI-101 toward the clinic. We are building on a compelling body of science with the potential to redefine how we treat this devastating disease.”
Alzheimer’s disease affects millions of people worldwide and often develops years or decades before symptoms appear. While many current research efforts focus on protein abnormalities such as amyloid and tau, growing scientific evidence suggests immune system dysfunction and chronic neuroinflammation also play major roles in disease progression.
MindImmune’s MITI-101 therapy is designed to target these immune-related mechanisms earlier in the disease process by modulating immune cell activity linked to sustained neuroinflammatory damage.
“Advancing scientific innovation in Alzheimer’s requires bold approaches that directly target the underlying biology and pathology of the disease,” said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. “Our investment in MindImmune and its lead candidate, MITI-101, reflects the ADDF’s commitment to advancing novel therapies that address key biological drivers like neuroinflammation. Targeting these mechanisms will be essential to a broader precision medicine framework to effectively treat and ultimately prevent Alzheimer’s.”
The investment will support key translational studies, preparation for an investigational new drug submission, and planning for early-stage clinical development of the therapy.
MindImmune said the funding reflects growing interest in immune-focused strategies as a potential new frontier in treating neurodegenerative diseases.
The Cambridge-based biotechnology company focuses on developing therapies that target immune pathways involved in neuroinflammation and disease progression across conditions such as Alzheimer’s disease.
